Background: Acute diffuse and total alopecia of the female scalp (ADTAFS) is a new subtype of alopecia areata that is characterized by rapid progression of diffuse alopecia of the female scalp, marked female predominance and a favorable prognosis. Differential diagnosis of other types of diffuse alopecia such as female pattern hair loss (FPHL) is necessary in some cases. Objective: To describe dermoscopic findings of ADTAFS and to investigate the possibility of utilizing dermoscopy as a diagnostic tool for ADTAFS. Methods: Twenty cases of ADTAFS diagnosed by clinical and/or histological findings were examined by dermoscopy. Results: Cadaverized hairs (black dots), exclamation mark hairs (tapering hairs), broken hairs or yellow dots were seen in 18, 13, 19 and 17 out of 20 cases, respectively. One of these signs was seen in all cases (20/20). On the other hand, none of 12 cases with exclusively FPHL showed the dermoscopic features such as cadaverized hairs, exclamation mark hairs or broken hairs. Only 1 FPHL patient showed a yellow dot in the hair loss area. Conclusion: Dermoscopy is a helpful diagnostic tool for ADTAFS, especially to distinguish it from FPHL.

Zalaudek I, Argenziano G, Di Stefani A, Ferrara G, Marghoob AA, Hofmann-Wellenhof R, Soyer HP, Braun R, Kerl H: Dermoscopy in general dermatology. Dermatology 2006;212:7–18.
Inui S, Nakajima T, Itami S: Dry dermoscopy in clinical treatment of alopecia areata. J Dermatol 2007;34:635–639.
Inui S, Nakajima T, Nakagawa K, Itami S: Clinical significance of dermoscopy in alopecia areata: analysis of 300 cases. Int J Dermatol 2008;47:688–693.
Inui S, Nakajima T, Shono F, Itami S: Dermoscopic findings in frontal fibrosing alopecia: report of four cases. Int J Dermatol 2008; 47:796–799.
Lacarrubba F, Dall’Oglio F, Rita Nasca M, Micali G: Videodermatoscopy enhances diagnostic capability in some forms of hair loss. Am J Clin Dermatol 2004;5:205–208.
Ross EK, Vincenzi C, Tosti A: Videodermoscopy in the evaluation of hair and scalp disorders. J Am Acad Dermatol 2006;55:799–806.
Tosti A: Alopecia areata; in Tosti A (ed): Dermoscopy of Hair and Scalp Disorders: Pathological and Clinical Correlation. London, Informa Healthcare, 2007, pp 26–44.
Tosti A: Alopecia areata incognita; in Tosti A (ed): Dermoscopy of Hair and Scalp Disorders: Pathological and Clinical Correlation. London, Informa Healthcare, 2007, pp 45–50.
Braun-Falco O, Zaun H: Über die Beteiligung des gesamten Capillitiums bei Alopecia areata. Hautarzt 1962;13:342–348.
Rebora A: Alopecia areata incognita: a hypothesis. Dermatologica 1987;174:214–218.
Chartier MB, Hoss DM, Grant-Kels JM: Approach to the adult female patient with diffuse nonscarring alopecia. J Am Acad Dermatol 2002;47:809–818, quiz 818–820.
Choi HJ, Ihm CW: Acute alopecia totalis. Acta Dermatovenerol Alp Panonica Adriat 2006;15:27–34.
Shapiro J, Madani S: Alopecia areata: diagnosis and management. Int J Dermatol 1999;38(suppl 1):19–24.
Sinclair R: Diffuse hair loss. Int J Dermatol 1999;38(suppl 1):8–18.
Sato-Kawamura M, Aiba S, Tagami H: Acute diffuse and total alopecia of the female scalp: a new subtype of diffuse alopecia areata that has a favorable prognosis. Dermatology 2002;205:367–373.
Nakajima T, Inui S, Itami S: Pulse corticosteroid therapy for alopecia areata: study of 139 patients. Dermatology 2007;215:320–324.
de Lacharriere O, Deloche C, Misciali C, Piraccini BM, Vincenzi C, Bastien P, Tardy I, Bernard BA, Tosti A: Hair diameter diversity: a clinical sign reflecting the follicle miniaturization. Arch Dermatol 2001;137:641–646.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.